-
New diabetes drug accepted for review by FDA
PRINCETON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a Type 2 diabetes drug from Bristol-Myers Squibb and AstraZeneca, the two drug makers said Tuesday.
The FDA accepted the application for dapagliflozin, an investigational drug for adults with the disease. The Centers for Disease Control and Prevention estimated that 1-in-11 U.S. adults has diabetes, with 90% to 95% of them having Type 2 diabetes.
The agency expects to take action on the application in late October.
-
3M debuts Cavilon antifungal cream
ST. PAUL, Minn. — 3M's skin and wound care division has launched an easy-to-apply cream that is designed to relieve skin discomforts caused by fungal infections.
New Cavilon antifungal cream, which is available in 2-oz. and 5-oz. tubes, is enriched with water-repelling ingredients, including 2% miconazole nitrate, an active ingredient that has been clinically proven to treat tinea corporis (ringworm), tinea pedis (athlete’s foot) and tinea cruris (jock itch), 3M said. The product also is approved for use on fungal infections caused by Candida albicans.